Bicycle Therapeutics Limited (NASDAQ:BCYC) Expected to Announce Earnings of -$0.54 Per Share

Analysts predict that Bicycle Therapeutics Limited (NASDAQ:BCYC) will announce ($0.54) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Bicycle Therapeutics’ earnings. The lowest EPS estimate is ($0.59) and the highest is ($0.47). The firm is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Bicycle Therapeutics will report full-year earnings of ($3.18) per share for the current year, with EPS estimates ranging from ($3.30) to ($3.06). For the next fiscal year, analysts expect that the business will report earnings of ($2.26) per share, with EPS estimates ranging from ($2.71) to ($1.58). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, November 7th. The company reported ($0.53) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.05. Bicycle Therapeutics had a negative return on equity of 238.49% and a negative net margin of 342.94%. The company had revenue of $0.61 million during the quarter, compared to the consensus estimate of $1.00 million.

A number of brokerages have commented on BCYC. Roth Capital began coverage on Bicycle Therapeutics in a research note on Thursday, November 14th. They issued a “buy” rating and a $17.00 target price for the company. Canaccord Genuity set a $22.00 target price on Bicycle Therapeutics and gave the company a “buy” rating in a research note on Monday, September 30th. Goldman Sachs Group upgraded Bicycle Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, September 11th. Finally, Zacks Investment Research upgraded Bicycle Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 26th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $19.00.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Monashee Investment Management LLC acquired a new stake in Bicycle Therapeutics during the 2nd quarter valued at $532,000. Pentwater Capital Management LP bought a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at about $642,000. Laurion Capital Management LP bought a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at about $1,006,000. Victory Capital Management Inc. bought a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at about $1,403,000. Finally, Atlas Venture Advisors Inc. bought a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at about $13,709,000. Institutional investors and hedge funds own 36.27% of the company’s stock.

Shares of BCYC stock opened at $8.76 on Friday. The company has a 50 day moving average of $9.19. Bicycle Therapeutics has a 52 week low of $6.24 and a 52 week high of $14.91.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Featured Article: How Short Selling Works

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.